manual-prevencion

MANUAL SEOM DE PREVENCIÓN Y DIAGNÓSTICO PRECOZ DEL CÁNCER 202 57. PadamseeTJ,Wills CE,Yee LD, Paskett ED. Decisionmaking for breast cancer prevention amongwomen at elevated risk. BreastCancer Res . 2017;19(1):34. doi:10.1186/s13058-017-0826-5. 58. Mocellin S, Pilati P, BriaravaM, Nitti D. Breast Cancer Chemoprevention: ANetworkMeta-Analysis of RandomizedControlledTrials. JNCI J Natl Cancer Inst . 2015;108(2):djv318-djv318. doi:10.1093/jnci/djv318. 59. Pastor-BarriusoR, AscunceN, EderraM, et al. Recalibrationof theGailmodel for predicting invasivebreast cancer risk in Spanishwomen: a population-based cohort study. BreastCancerResTreat . 2013;138(1):249-259. doi:10.1007/s10549-013-2428-y. 60. EuropeanCouncil. Recommendationof 2December onCancer Screening. OffJEurUnion . 2003;878:34-38. 61. ORden SSI/2065/2014, de 31de octubre, por la que semodifican los anexos I, II y III del Real Decreto1030/2006, de 15de septiembre, por leque se establece la cartera de servicios comunes del SistemaNacional de Salud y el procedimientopara su actualiz. 62. Gøtzsche PC, OlsenO. Is screening for breast cancerwithmammography justifiable? Lancet . 2000;355(9198):129-134. doi:10.1016/ S0140-6736(99)06065-1. 63. HealthCouncil of theNetherlands. PopulationScreening forBreastCancer: ExpectationsandDevelopments . LaHague; 2014. 64. Uk I, Cancer B.Thebenefits andharms of breast cancer screening: an independent review. Lancet . 2012;380(9855):1778-1786. doi:10.1016/S0140-6736(12)61611-0. 65. BroedersM, Moss S, NyströmL, et al.The Impact ofMammographic ScreeningonBreast CancerMortality in Europe: AReviewof Observational Studies. JMedScreen . 2012;19(1_suppl):14-25. doi:10.1258/jms.2012.012078. 66. Duffy SW, ChenHH, SmithRA,YenAMF,Tabar L. Real and artificial controversies inbreast cancer screening. BreastCancerManag . 2013;2(6):519-528. 67. WHOPositionPaper onMammography Screening. 2014. 68. Béatrice Lauby Secretan, Ph.D., Chiara Scoccianti, Ph.D., Dana Loomis, Ph.D., et al. Breast-Cancer Screening.Viewpoint of the IARC WorkingGroup. NEngl JMed. 2015; 372:2353-235 8 http://www.nejm.org/toc/nejm/372/24/ 69. Puliti D, Duffy SW, Miccinesi G, et al. Overdiagnosis inmammographic screening for breast cancer in Europe: a literature review. JMed Screen . 2012;19 Suppl 1(1_suppl):42-56. doi:10.1258/jms.2012.012082. 70. RomanR, SalaM, SalasD, et al. Effect of protocol-related variables andwomen’s characteristics on the cumulative false-positive risk in breast cancer screening. AnnOncol . 2012;23(1):104-111. doi:10.1093/annonc/mdr032. 71. Paci E, EUROSCREENWorkingGroup. Summary of the Evidence of Breast Cancer Service ScreeningOutcomes in Europe and First Estimate of the Benefit andHarmBalance Sheet. JMedScreen . 2012;19(1_suppl):5-13. doi:10.1258/jms.2012.012077. 72. Ponti A, AnttilaA, RoncoG, editors. Cancer Screening inReportonthe Implementationof theCouncil Recommendation onCancer Screening . Lyon; 2017. https://ec.europa.eu/health/sites/health/files/major_chronic_diseases/docs/2017_ cancerscreening_2ndreportimplementation_en.pdf. AccessedMay 10, 2017.